GSK2606414

GSK2606414 is a selective inhibitor of the protein kinase PERK, which is involved in the unfolded protein response. It has been studied for its potential use in the treatment of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

Mechanism of Action[edit | edit source]

GSK2606414 works by inhibiting the protein kinase PERK. PERK is one of three major signaling pathways of the unfolded protein response (UPR), which is activated in response to the accumulation of unfolded proteins in the endoplasmic reticulum (ER). By inhibiting PERK, GSK2606414 reduces the level of ER stress and the subsequent cell death that can occur in neurodegenerative diseases.

Potential Therapeutic Uses[edit | edit source]

Research has suggested that GSK2606414 may have potential therapeutic uses in the treatment of neurodegenerative diseases. In preclinical studies, it has been shown to reduce the level of ER stress and cell death in neurons, suggesting that it may have neuroprotective effects.

In a study on a mouse model of prion disease, treatment with GSK2606414 was found to delay the onset of clinical signs and extend survival. However, the treatment also caused side effects including weight loss and hyperglycemia.

Side Effects[edit | edit source]

The most common side effects of GSK2606414 in preclinical studies have been weight loss and hyperglycemia. These side effects are believed to be due to the inhibition of PERK in peripheral tissues.

Future Research[edit | edit source]

Further research is needed to determine the safety and efficacy of GSK2606414 in humans. In particular, studies are needed to determine the optimal dosing regimen and to further investigate the potential side effects.